At a glance
ClinicalIndex Comparison Record- ✓Diagnosis of severe aplastic anemia that failed at least 1 course of standard immunosuppressive regimen with cyclosporine and anti-thymocyte globulin
- ✓Acute leukemia (AML with antecedent MDS, secondary AML, or high-risk cytogenetics; or ALL with high-risk cytogenetics) with resistant/recurrent disease after combination chemotherapy or in first remission at high risk of relapse
- ✓Chronic myelogenous leukemia in chronic phase (failed imatinib, failed interferon after 6+ months, or intolerant to interferon) or accelerated phase with <20% blasts
- ✓Myeloproliferative and myelodysplastic syndromes including myelofibrosis (after splenectomy), refractory anemia, refractory anemia with excess blasts, or chronic myelomonocytic leukemia
- ✕Uncontrolled CNS disease for hematologic malignancies
- ✕Syngeneic donors not permitted
- ✕HIV antibody positive
- ✕Active serious infection
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Non-Myeloablative Allogeneic Hematopoietic Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies and Disorders
In Brief
A Phase 2 clinical trial evaluating anti-thymocyte globulin, graft-versus-tumor induction therapy, and 10 other interventions for Chronic Myeloproliferative Disorders and 7 related conditions. Completed, enrolled 41 participants across 1 site.
Detailed Summary
RATIONALE: Giving low doses of chemotherapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune system and help destroy any remaining cancer cells (graft-versus-tumor effect). Giving an infusion of the donor's T cells (donor lymphocyte infusion) after the transplant may help increase this effect. Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving immunosuppressive therapy before or after the transplant may stop this from happening. PURPOSE: This phase II trial is studying how well chemotherapy followed by donor peripheral stem cell transplant works in treating patients with hematologic cancer or aplastic anemia.
Study Details
Timeline
Interventions
iv
iv
iv
iv
injection
iv
oral
oral
oral
iv
iv
iv